Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer patients: lorlatinib shows promise in taiwan study

NCT ID NCT06282991

Completed Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

First seen Mar 16, 2026 · Last updated May 09, 2026 · Updated 5 times

Summary

This study looked at how well the drug lorlatinib works for people with advanced non-small cell lung cancer that has a specific gene change (ALK). All 73 participants had already tried other treatments and their cancer was no longer controlled. The study found that lorlatinib helped shrink tumors and control the cancer for a period of time, but it is not a cure. Common side effects included high cholesterol, high blood sugar, rash, and swelling.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CHANG GUNG MEMORIAL HOSPITAL Kaohsiung Branch

    Kaohsiung City, 83301, Taiwan

  • Chang Gung Memorial Hospital - Linkou Branch

    Taoyuan City, 333, Taiwan

  • Chung Shan Medical University Hospital

    Taichung, 402, Taiwan

  • National Taiwan University Hospital

    Taipei, 100, Taiwan

  • Taichung Veterans General Hospital

    Taichung, 407219, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

Conditions

Explore the condition pages connected to this study.

NON-SMALL CELL LUNG CARCINOMA NON-SMALL CELL LUNG CARCINOMA